A detailed history of Baker Bros. Advisors LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 464,718 shares of IMVT stock, worth $12.8 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
464,718
Previous 425,009 9.34%
Holding current value
$12.8 Million
Previous $13.7 Million 10.66%
% of portfolio
0.16%
Previous 0.17%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $996,695 - $1.26 Million
39,709 Added 9.34%
464,718 $12.3 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $7.88 Million - $17 Million
425,009 New
425,009 $16.3 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.